Pharmaceutical company STADA said it is expanding its consumer healthcare business in the Asia-Pacific region with the acquisition of Nizoral Cream from Janssen Pharmaceutica NV, a Johnson & Johnson company.
The product with the active ingredient ketoconazole is indicated for the treatment of fungal skin infections.
Under the terms of the agreement, STADA acquires the existing distribution and Nizoral Cream business in the Philippines, Vietnam and Thailand as well as the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore.
The transaction in an extension of a previous asset deal to the APAC region. In 2018, STADA acquired the Nizoral brand in key EMEA markets.
“We are delighted to take this important step of expansion in the Asia-Pacific region. This partnership further strengthens STADA´s role as a partner of choice in consumer healthcare,” said STADA executive vice president for emerging markets Stephane Jacqmin.
